{
    "nctId": "NCT01501266",
    "briefTitle": "Faslodex Specific Clinical Experience Investigation",
    "officialTitle": "Faslodex Specific Clinical Experience Investigation for Long-term Use",
    "overallStatus": "COMPLETED",
    "conditions": "Breast Cancer",
    "studyType": "OBSERVATIONAL",
    "phase": "N/A",
    "allocation": "N/A",
    "primaryPurpose": "N/A",
    "enrollmentCount": 660,
    "primaryOutcomeMeasure": "Incidence of adverse drug reactions.",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Patients treated with Faslodex for the first time due to postmenopausal breast cancer\n\nExclusion Criteria:\n\n* None",
    "sex": "FEMALE",
    "minimumAge": "N/A",
    "stdAges": "CHILD, ADULT, OLDER_ADULT"
}